A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy
Titel:
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy
Auteur:
Scagliotti, Giorgio Nishio, Makoto Satouchi, Miyako Valmadre, Giuseppe Niho, Seiji Galetta, Domenico Cortinovis, Diego Benedetti, Fabio Yoshihara, Eiji Makris, Lukas Inoue, Akira Kubota, Kaoru